Erlotinib for the Treatment of Non-Small Cell Lung Cancer Technology Appraisal
Country of origin: UK
If the overall treatment cost is equal, specialists should discuss with patients the potential benefits and risks of erlotinib and docetaxel before deciding which treatment to use.
Erlotinib is not recommended for people with locally advanced or metastatic NSCLC who cannot take docetaxel and have already tried one chemotherapy regimen but it has not worked.
Erlotinib is not recommended for people who have already tried two chemotherapy regimens, including docetaxel, but they haven't worked.
Healthcare professionals should not stop prescribing erlotinib for people who were already taking it when the guidance was issued. These patients should be able to carry on taking erlotinib until they and their specialist decide that it is the right time to stop treatment.
'Lung cancer (non-small-cell) - erlotinib: guidance ' is available online.
Institute of Cancer Research February 2019
Researchers in bowel cancer discovery February 2019
inPractice® Oncology. January 2019
Prostate cancer report January 2019
Manual for Cancer Services: Chemotherapy Measures November 2018
Sublux radiology app for all medical providers October 2018